Jill Wykosky

Jill Wykosky

UNVERIFIED PROFILE

Are you Jill Wykosky?   Register this Author

Register author
Jill Wykosky

Jill Wykosky

Publications by authors named "Jill Wykosky"

Are you Jill Wykosky?   Register this Author

20Publications

535Reads

48Profile Views

A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.

Cancer Res 2015 Jan 28;75(2):394-404. Epub 2014 Nov 28.

Ludwig Institute for Cancer Research, La Jolla, California. Department of Pathology, University of California San Diego, La Jolla, California. The Moores Cancer Center, University of California San Diego, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-2004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297573PMC
January 2015

Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.

Cancer Biol Med 2013 Dec;10(4):192-205

Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7497/j.issn.2095-3941.2013.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860350PMC
December 2013

EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.

Mol Cell Biol 2012 Aug 11;32(16):3253-64. Epub 2012 Jun 11.

Department of Neurosurgery, Brain Tumor Center of Excellence, Comprehensive Cancer Center of Wake Forest University, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

View Article

Download full-text PDF

Source
http://mcb.asm.org/cgi/doi/10.1128/MCB.06791-11
Publisher Site
http://dx.doi.org/10.1128/MCB.06791-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434542PMC
August 2012

Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

J Biol Chem 2012 Apr 23;287(17):14012-22. Epub 2012 Feb 23.

Brain Tumor Center of Excellence, Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, North Carolina 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M111.311670DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340174PMC
April 2012

Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.

Chin J Cancer 2011 Jan;30(1):5-12

Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, California 92093-0660, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359794PMC
January 2011

Escape from targeted inhibition: the dark side of kinase inhibitor therapy.

Cell Cycle 2010 May 16;9(9):1661-2. Epub 2010 May 16.

Ludwig Institute for Cancer Research, University of California San Diego, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.9.9.11592DOI Listing
May 2010

Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.

Proc Natl Acad Sci U S A 2010 Feb 21;107(6):2616-21. Epub 2010 Jan 21.

Ludwig Institute for Cancer Research, University of California, San Diego, CA 92039, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0914356107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2823874PMC
February 2010

The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Mol Cancer Res 2008 Dec;6(12):1795-806

Department of Neurosurgery, Brain Tumor Center of Excellence, Comprehensive Cancer Center of Wake Forest University, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-08-0244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3690928PMC
December 2008

Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy.

Clin Cancer Res 2008 Jan;14(1):199-208

Brain Tumor Center of Excellence, Comprehensive Cancer Center, Department of Neurosurgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1990DOI Listing
January 2008

A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.

Mol Cancer Ther 2007 Dec;6(12 Pt 1):3208-18

Department of Neurosurgery, Brain Tumor Center of Excellence, Comprehensive Cancer Center of Wake Forest University, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0200DOI Listing
December 2007

EphA2 as a novel molecular marker and target in glioblastoma multiforme.

Mol Cancer Res 2005 Oct;3(10):541-51

Brain Tumor Center of Excellence, Comprehensive Cancer Center, Department of Neurosurgery, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-05-0056DOI Listing
October 2005